Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C29H26ClFN4O3S |
| Molecular Weight | 565.058 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[S+]([O-])CCNCC1=CC=C(O1)C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2
InChI
InChIKey=OAMVGUFHZPRXOM-UHFFFAOYSA-N
InChI=1S/C29H26ClFN4O3S/c1-39(36)12-11-32-16-23-7-10-27(38-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)37-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
Qilu Pharmaceutical has developed selatinib, an orally available dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 receptor (HER-2) for the treatment of cancer. Selatinib participates in phase I of the ongoing clinical trial to evaluate its safety and tolerability, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients with advanced breast cancer.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1275595-86-2
Created by
admin on Mon Mar 31 22:36:12 GMT 2025 , Edited by admin on Mon Mar 31 22:36:12 GMT 2025
|
PRIMARY | |||
|
6TLR8U8O3C
Created by
admin on Mon Mar 31 22:36:12 GMT 2025 , Edited by admin on Mon Mar 31 22:36:12 GMT 2025
|
PRIMARY | |||
|
C213712
Created by
admin on Mon Mar 31 22:36:12 GMT 2025 , Edited by admin on Mon Mar 31 22:36:12 GMT 2025
|
PRIMARY | |||
|
51348455
Created by
admin on Mon Mar 31 22:36:12 GMT 2025 , Edited by admin on Mon Mar 31 22:36:12 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
